Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,79.88,13278,DB00711,Diethylcarbamazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,90.71,13279,DB00711,Diethylcarbamazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,85.72,13280,DB00711,Diethylcarbamazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,93.17,13281,DB00711,Diethylcarbamazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,94.38,13282,DB00711,Diethylcarbamazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,101.00,13283,DB00711,Diethylcarbamazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,99.87,13284,DB00711,Diethylcarbamazine
,30947125,run time,"Separation of all analytes was performed on a Xselect CSH™ C18 HPLC column (Waters, 3.0 x 150 mm, 3.5 μm particle size) with gradient elution employing a mobile phase consisting of 0.1% v/v formic acid in water and methanol with a run time of 20 min.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),min,20,13285,DB00711,Diethylcarbamazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,445.4,13286,DB00711,Diethylcarbamazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,200.2,13287,DB00711,Diethylcarbamazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,282.3,13288,DB00711,Diethylcarbamazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,298.3,13289,DB00711,Diethylcarbamazine
,24847779,maximum entrapment efficiency,The size of the spherical particles was in the range of 27.25 ± 3.43 nm to 179 ± 3.08 nm and a maximum entrapment efficiency of 68.63 ± 1.53% was observed.,Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847779/),%,68.63,21234,DB00711,Diethylcarbamazine
,24847779,maximum time,In vitro release studies in pH 7.4 PBS displayed a rapid release and the maximum time taken for the complete drug to release was 150 min.,Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847779/),min,150,21235,DB00711,Diethylcarbamazine
,10784424,plasma-saliva concentration ratio,The plasma-saliva concentration ratio was calculated as 1.53 whereas the observed ratio was 3.82.,Pharmacokinetics of diethylcarbamazine: prediction by concentration in saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784424/),,1.53,32438,DB00711,Diethylcarbamazine
,11865970,Cmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ng] / [ml],500,49891,DB00711,Diethylcarbamazine
,11865970,Cmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ng] / [ml],637,49892,DB00711,Diethylcarbamazine
,11865970,tmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,2.3,49893,DB00711,Diethylcarbamazine
,11865970,tmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,2.7,49894,DB00711,Diethylcarbamazine
,11865970,Ka,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),1/[h],2.23,49895,DB00711,Diethylcarbamazine
,11865970,Ka,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),1/[h],1.96,49896,DB00711,Diethylcarbamazine
,11865970,t1/2,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,14.6,49897,DB00711,Diethylcarbamazine
,11865970,t1/2,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,11.4,49898,DB00711,Diethylcarbamazine
,11865970,AUC0-t,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"5,334",49899,DB00711,Diethylcarbamazine
,11865970,AUC0-t,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"6,901",49900,DB00711,Diethylcarbamazine
,11865970,AUC0-infinity,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"5,840",49901,DB00711,Diethylcarbamazine
,11865970,AUC0-infinity,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"7,220",49902,DB00711,Diethylcarbamazine
,11865970,CL/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ml] / [h·kg],"36,058",49903,DB00711,Diethylcarbamazine
,11865970,CL/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ml] / [h·kg],"32,189",49904,DB00711,Diethylcarbamazine
,11865970,Vd/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),l,570,49905,DB00711,Diethylcarbamazine
,11865970,Vd/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),l,533,49906,DB00711,Diethylcarbamazine
,9518148,limit of detection,The limit of detection is 4 ng/ml.,Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518148/),[ng] / [ml],4,84765,DB00711,Diethylcarbamazine
,9518148,Recovery,Recovery following solid-phase extraction is 99.3% for DEC and 94.8% for the internal standard.,Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518148/),%,99.3,84766,DB00711,Diethylcarbamazine
,9518148,Recovery,Recovery following solid-phase extraction is 99.3% for DEC and 94.8% for the internal standard.,Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518148/),%,94.8,84767,DB00711,Diethylcarbamazine
,25339590,Relative bioavailability,Relative bioavailability of carbamazepine after administration of nanoemulsion was 160% compared to unmodified substance.,Experimental investigation of pharmacodynamics and pharmacokinetics of carbamazepine nanoemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25339590/),%,160,105602,DB00711,Diethylcarbamazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],35,132227,DB00711,Diethylcarbamazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],1.5,132228,DB00711,Diethylcarbamazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],25,132229,DB00711,Diethylcarbamazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],420,132230,DB00711,Diethylcarbamazine
,11516918,retention times,"The retention times of DEC and internal standard were approximately 5.5 and 7.28 min, respectively.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),min,5.5,132231,DB00711,Diethylcarbamazine
,11516918,retention times,"The retention times of DEC and internal standard were approximately 5.5 and 7.28 min, respectively.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),min,7.28,132232,DB00711,Diethylcarbamazine
,11516918,run time,The GC run time was 22 min.,Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),min,22,132233,DB00711,Diethylcarbamazine
,24975211,retention time,The retention time was approximately 4.8min.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),min,4.8,180933,DB00711,Diethylcarbamazine
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,84.2,180934,DB00711,Diethylcarbamazine
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,90.1,180935,DB00711,Diethylcarbamazine
,23828187,peak plasma concentration,"To substantiate increase in MIF activity, pharmacokinetics study was designed on Wistar rats which revealed a greater peak plasma concentration (45.3 ± 1.79 ng/ml), area under the concentration curve (298 ± 38.7 ng d/ml) and extended mean residence time (23.4 ± 8.56 days)of IVM in chitosan-alginate nanoparticles.","Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23828187/),[ng] / [ml],45.3,202676,DB00711,Diethylcarbamazine
,23828187,area under the concentration curve,"To substantiate increase in MIF activity, pharmacokinetics study was designed on Wistar rats which revealed a greater peak plasma concentration (45.3 ± 1.79 ng/ml), area under the concentration curve (298 ± 38.7 ng d/ml) and extended mean residence time (23.4 ± 8.56 days)of IVM in chitosan-alginate nanoparticles.","Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23828187/),[d·ng] / [ml],298,202677,DB00711,Diethylcarbamazine
,23828187,mean residence time,"To substantiate increase in MIF activity, pharmacokinetics study was designed on Wistar rats which revealed a greater peak plasma concentration (45.3 ± 1.79 ng/ml), area under the concentration curve (298 ± 38.7 ng d/ml) and extended mean residence time (23.4 ± 8.56 days)of IVM in chitosan-alginate nanoparticles.","Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23828187/),d,23.4,202678,DB00711,Diethylcarbamazine
,9602386,limit of detection,The intra- and inter-assay coefficient of variation was < 10% in the range of 1.0-30 ng ml-1 and the limit of detection was 0.3 ng ml-1.,"A direct competitive ELISA for the simple, sensitive and accurate determination of diethylcarbamazine concentration in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602386/),[ng] / [ml],0.3,247310,DB00711,Diethylcarbamazine
<,9602386,cross reactivities,The cross reactivities of anti-diethylcarbamazine antibodies with diethylcarbamazine metabolites and ivermectin were < 0.09%.,"A direct competitive ELISA for the simple, sensitive and accurate determination of diethylcarbamazine concentration in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602386/),%,0.09,247311,DB00711,Diethylcarbamazine
,7285488,peak plasma concentration,"DEC appeared to be rapidly absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr.",Diethylcarbamazine disposition in patients with onchocerciasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285488/),[ng] / [ml],150 to 250,259853,DB00711,Diethylcarbamazine
